

Table S1 Characteristics of respondents and non-respondents

Variables	Total (N=19,026)	Non-respondents (N=13,290)	Respondents (N=5,736)	P value
Age (years)				
0–17	4,289 (22.5)	3,038 (22.9)	1,251 (21.8)	<0.001
18–29	3,599 (18.9)	2,852 (21.5)	747 (13.0)	
30–39	3,426 (18.0)	2,637 (19.8)	789 (13.8)	
40–49	3,441 (18.1)	2,388 (18.0)	1,053 (18.4)	
50–64	2,949 (15.5)	1,761 (13.3)	1,188 (20.7)	
65+	1,322 (6.9)	614 (4.6)	708 (12.3)	
Sex				
Male	10,019 (52.7)	7,291 (54.9)	2,728 (47.6)	<0.001
Female	9,007 (47.3)	5,999 (45.1)	3,008 (52.4)	
Residence				
Within the city	12,394 (65.1)	8,657 (65.1)	3,737 (65.1)	0.12
Within the prefecture	6,194 (32.6)	4,346 (32.7)	1,848 (32.2)	
Other	438 (2.3)	287 (2.2)	151 (2.6)	
PCR result				
Negative	7,847 (41.2)	5,783 (43.5)	2,064 (36.0)	<0.001
Positive	10,977 (57.7)	7,374 (55.5)	3,603 (62.8)	
No-test	202 (1.1)	133 (1.0)	69 (1.2)	

Values expressed in n (%). PCR, polymerase chain reaction.

Table S2 Symptoms of patients in this study, before summarizing (n=4,779)

Symptoms	Total (N=4,779)	SARS-CoV-2 never-infected group (N=1,453)	SARS-CoV-2 infected group (N=3,326)	P value
Cough	570 (11.9)	147 (10.1)	423 (12.7)	0.01
Sputum	470 (9.8)	133 (9.2)	337 (10.1)	0.30
Dyspnea	109 (2.3)	19 (1.3)	90 (2.7)	0.003
Chest discomfort	70 (1.5)	15 (1.0)	55 (1.7)	0.10
Fever	237 (5.0)	68 (4.7)	169 (5.1)	0.56
Musculoskeletal pain	291 (6.1)	112 (7.7)	179 (5.4)	0.002
Headache	650 (13.6)	208 (14.3)	442 (13.3)	0.34
Throat pain	360 (7.5)	113 (7.8)	247 (7.4)	0.67
Loss of taste	49 (1.0)	5 (0.3)	44 (1.3)	0.002
Loss of smell	47 (1.0)	3 (0.2)	44 (1.3)	<0.001
Cognitive impairment	204 (4.3)	36 (2.5)	168 (5.1)	<0.001
Insomnia	154 (3.2)	36 (2.5)	118 (3.5)	0.054
Fatigue	562 (11.8)	154 (10.6)	408 (12.3)	0.10
Muscle weakness	120 (2.5)	28 (1.9)	92 (2.8)	0.09
Diarrhea	235 (4.9)	71 (4.9)	164 (4.9)	0.95
Hair loss	103 (2.2)	11 (0.8)	92 (2.8)	<0.001

Values expressed in n (%). SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.

Table S3 Sensitivity analysis: Multivariate logistic analysis using the data excluding patients among the infected group who had a history of infection before the study period or had unknown infection dates (n=4,334)

SARS-CoV-2 infection status	aOR	95% CI
Respiratory symptoms (ref. never)		
Infected	1.22	1.02–1.47
Common cold symptoms		
Infected	0.80	0.68–0.94
Loss of taste and/or smell		
Infected	4.00	1.69–9.45
Neurocognitive symptoms		
Infected	1.93	1.41–2.64
General symptom		
Infected	1.14	0.93–1.41
Diarrhea		
Infected	0.93	0.68–1.26
Hair loss		
Infected	3.48	1.82–6.66

Adjusted for age, sex, body mass index, smoking status, comorbidities, working status, and SARS-CoV-2 vaccination doze at the time of response. SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; aOR, adjusted odds ratio; CI, confidence interval.